TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc. (TLSI): 3 pipeline candidates · ~28 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
27.8 months
D/E 4.54 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
12 buys · 15 sells (180d)
A transparent, data-derived signal for TriSalus Life Sciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$257.0M
Cash
$56.6M
Quarterly Burn
$6.5M
Runway
27.8 mo
Revenue
$8.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| anti-pd-1 | Phase 1 |
| nelitolimod | Phase 1 |
| sd-101 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
81
Total value held
$46.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,694,072 | $10.8M |
| blackrock, inc. | 1,499,547 | $6.0M |
| wasatch advisors lp | 1,437,960 | $5.8M |
| gilder gagnon howe & co llc | 888,515 | $3.6M |
| geode capital management, llc | 777,094 | $3.1M |
| kennedy capital management llc | 485,242 | $1.9M |
| morgan stanley | 393,909 | $1.6M |
| state street corp | 328,020 | $1.3M |
| empire financial management company, llc | 300,275 | $1.2M |
| perkins capital management inc | 230,101 | $920K |
Showing top 10 of 81 institutional holders of TriSalus Life Sciences Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in TriSalus Life Sciences Inc.'s pipeline?
TriSalus Life Sciences Inc. (TLSI) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TriSalus Life Sciences Inc.'s lead drug candidate?
TriSalus Life Sciences Inc.'s most advanced tracked candidate is anti-pd-1 (Phase 1) for Locally Advanced Pancreatic Adenocarcinoma.
What is TriSalus Life Sciences Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TriSalus Life Sciences Inc. has approximately 27.8 months of cash runway.
What is TriSalus Life Sciences Inc.'s market capitalization?
TriSalus Life Sciences Inc.'s market capitalization is approximately $257.0M.
Who is the CEO of TriSalus Life Sciences Inc.?
Ms. Mary T. Szela B.S.N., M.B.A. is the chief executive officer of TriSalus Life Sciences Inc. (TLSI).
Get the full picture on TriSalus Life Sciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.